YONGKANG SHI, JUN MA, KE CHEN, BIN CHEN^*

Oncology Research, Vol.30, No.4, pp. 201-210, 2022, DOI:10.32604/or.2022.027584 - 31 January 2023

Abstract 5-Fluorouracil (5-FU) is a commonly used chemotherapeutic agent for various cancers. However, the drug resistance developed by tumor cells hinders the therapeutic effect. Konjac glucomannan (KGM) is indicated to sensitize 5-FU-resistant hepatocellular carcinoma (HCC) cells to 5-FU. In our study, we found that KGM or 5-FU treatment alone did not affect the malignant cell behaviors and endoplasmic reticulum (ER) stress of 5-FU-resistant HCC cells or HepG2/5-FU and Bel-7402/5-FU cells, while cotreatment with KGM and 5-FU significantly facilitated HCC cell apoptosis and ER stress and suppressed cell proliferation potential and migration abilities. Moreover, we explored the… More >

Jianglin Zhao¹, Xiaotong Zhang¹, Weiwei Lei¹, Xingqi Ji¹, Xin Zhou^1,2,*, Yong Xu^1,2

Journal of Renewable Materials, Vol.8, No.1, pp. 79-88, 2020, DOI:10.32604/jrm.2020.08761 - 01 January 2020

Abstract Amorphophallus konjac is rich in glucomannan, which can be hydrolyzed into glucose and mannose, thereby acting as an economic raw material for the acquisition of glucose and mannose. The total sugar yield was 91.2% when konjac powder was treated with 0.75% hydrochloric acid at 121°C for 1 h. Thus, dilute acid hydrolysates of konjac powder were used as a carbon source for obtaining value-added products. Here we showed that the microbial production of ethanol and mannonic acid was obtained by employing Candida shehatae (C. shehatae) and Gluconobacter oxydans (G. oxydans). Through a step-by-step bioprocess, glucose is the first selectively converted More >